Nitto Avecia
Nitto Avecia, a prominent player in the biotechnology and pharmaceutical sectors, is headquartered in the United States. Founded in 1998, the company has established itself as a leader in contract development and manufacturing, specialising in the production of biologics and advanced therapies. With operational facilities across key regions in the US, Nitto Avecia is renowned for its commitment to quality and innovation. The company offers a range of core services, including plasmid DNA production, viral vector manufacturing, and cell line development, all tailored to meet the unique needs of its clients. Nitto Avecia's state-of-the-art technologies and rigorous quality control processes set it apart in a competitive market. Recognised for its significant contributions to the industry, Nitto Avecia continues to drive advancements in biopharmaceutical manufacturing, solidifying its position as a trusted partner for companies seeking reliable and efficient solutions.
DitchCarbon Score
How does Nitto Avecia's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Nitto Avecia's score of 8 is lower than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Nitto Avecia's reported carbon emissions
In 2023, Nitto Avecia reported total carbon emissions of approximately 525,000,000 kg CO2e for both Scope 1 and Scope 2 emissions. This figure reflects their direct emissions from owned or controlled sources and indirect emissions from the generation of purchased electricity, steam, heating, and cooling consumed by the company. In 2022, the company disclosed a significant Scope 3 emissions total of about 2,622,000,000 kg CO2e, which encompasses a wide range of indirect emissions, including those from franchises, investments, and the use of sold products. Nitto Avecia has committed to near-term reduction targets, although specific numerical targets have not been disclosed. The company is not currently committed to a net-zero target. Their climate initiatives are aligned with industry standards in the pharmaceuticals, biotechnology, and life sciences sector, reflecting a growing awareness and responsibility towards climate impact. Overall, Nitto Avecia's emissions data and commitments indicate a proactive approach to managing their carbon footprint, with a focus on both direct and indirect emissions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | |
|---|---|---|
| Scope 1 | - | 000,000,000 |
| Scope 2 | - | 000,000,000 |
| Scope 3 | 2,622,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Nitto Avecia is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
